Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 2/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | CDK8 | P49336 | 1/20 | 0.58 |
| ▸ | RAF1 | P04049 | 3/20 | 0.56 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.56 |
| ▸ | CASR | P41180 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273474 | 0.90 | TRPV1 (0.57) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL13556629 | 0.84 | RAF1 (0.72) | KDRCA1CA2CA7CA9 | |
| SCHEMBL16620661 | 0.84 | KDR (0.72) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL18615348 | 0.84 | KDR (0.85) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL4118152 | 0.83 | LMNA (0.72) | KDRCA1CA2CA7CA9 | |
| SCHEMBL672388 | 0.81 | RAF1 (0.74) | KDRCA1CA2CA7CA9 | |
| SCHEMBL21295527 | 0.80 | MEN1 (0.77) | CA1CA2CA9NOX1 | |
| SCHEMBL29364392 | 0.80 | KDR (1.00) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL118026 | 0.80 | KDR (1.00) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL28901340 | 0.79 | KDR (0.76) | KDRTRPV1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065734-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | 4SC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2220042-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | 4SC AG (DE) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009063054-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | 4SC AG (DE) | 2009-05-22 | — | — | WO | disclosed |
| EP-2060565-A1 | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases | 4SC AG (DE) | 2009-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065734-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | HDAC1, HDAC11, MAP2K2 | KDR 2658/4885TRPV1 4293/4885CA1 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.